Medical therapy for ulcerative colitis 2004

被引:138
作者
Hanauer, SB [1 ]
机构
[1] Univ Chicago, Dept Med, Sect Gastroenterol & Nutr, Chicago, IL 60637 USA
关键词
D O I
10.1053/j.gastro.2004.02.071
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
There continue to be evolutionary changes in the management of ulcerative colitis despite the fact that, aside from a variety of aminosalicylate formulations, no new therapies have been approved over the past few decades. Nevertheless, debates continue regarding the optimization of treatment with aminosalicylates and the short- and long-term benefits of immunomodulation in ulcerative colitis. This article focuses on the most recent clinical studies pertaining to the management of ulcerative colitis and explores both the advances and controversies pertaining to aminosalicylate therapy, corticosteroids, cyclosporine, and the purine antimetabolites. Novel therapeutic approaches-including preliminary experience with biological therapies directed at tumor necrosis factor and other cytokines, adhesion molecules, growth factors, and probiotics-will be reviewed. Recent data regarding potential chemoprevention in long-standing ulcerative colitis and management of postoperative complications and pouchitis will also be discussed.
引用
收藏
页码:1582 / 1592
页数:11
相关论文
共 132 条
  • [1] CONTINUOUSLY INFUSED CYCLOSPORINE AT LOW-DOSE IS SUFFICIENT TO AVOID EMERGENCY COLECTOMY IN ACUTE ATTACKS OF ULCERATIVE-COLITIS WITHOUT THE NEED FOR HIGH-DOSE STEROIDS
    ACTIS, GC
    OTTOBRELLI, A
    PERA, A
    BARLETTI, C
    PONTI, V
    PINNAPINTOR, M
    VERME, G
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 1993, 17 (01) : 10 - 13
  • [2] Infliximab for treatment of steroid-refractory ulcerative colitis
    Actis, GC
    Bruno, M
    Pinna-Pintor, M
    Rossini, FP
    Rizzetto, M
    [J]. DIGESTIVE AND LIVER DISEASE, 2002, 34 (09) : 631 - 634
  • [3] Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: An open-label retrospective trial
    Actis, GC
    Aimo, G
    Priolo, G
    Moscato, D
    Rizzetto, M
    Pagni, R
    [J]. INFLAMMATORY BOWEL DISEASES, 1998, 4 (04) : 276 - 279
  • [4] Safety and efficacy of azathioprine in the maintenance of ciclosporin-induced remission of ulcerative colitis
    Actis, GC
    Bresso, F
    Astegiano, M
    Demarchi, B
    Sapone, N
    Boscaglia, C
    Rizzetto, M
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (09) : 1307 - 1311
  • [5] ADLER DJ, 1990, AM J GASTROENTEROL, V85, P717
  • [6] Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease
    Allgayer, H
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 : 10 - 14
  • [7] Growth factors in inflammatory bowel disease
    Beck, PL
    Podolsky, DK
    [J]. INFLAMMATORY BOWEL DISEASES, 1999, 5 (01) : 44 - 60
  • [8] Berndtsson I, 2003, Colorectal Dis, V5, P173, DOI 10.1046/j.1463-1318.2003.00455.x
  • [9] Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?
    Bernstein, CN
    Blanchard, JF
    Metge, C
    Yogendran, M
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (12) : 2784 - 2788
  • [10] Oral tacrolimus treatment of severe colitis in children
    Bousvaros, A
    Kirschner, BS
    Werlin, SL
    Parker-Hartigan, L
    Daum, F
    Freeman, KB
    Balint, JP
    Day, AS
    Griffiths, AM
    Zurakowski, D
    Ferry, GD
    Leichtner, AM
    [J]. JOURNAL OF PEDIATRICS, 2000, 137 (06) : 794 - 799